Challenges in biomarker discovery: Combining expert insights with statistical analysis of complex omics data

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 1, 2013, Pages 37-51

  McDermott, Jason E ^a   Wang, Jing ^a   Mitchell, Hugh ^a   Webb Robertson, Bobbie Jo ^a   Hafen, Ryan ^a   Ramey, John ^a   Rodland, Karin D ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

Biomarkers; Classification; Data integration; Expert knowledge; Molecular signatures

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBRIN; FIBRIN DEGRADATION PROTEIN; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MUCIN; NANOPARTICLE; NUCLEAR MATRIX PROTEIN 22; OSTEOPONTIN; PROGESTERONE RECEPTOR; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; SOMATOMEDIN B; TENASCIN; THYROGLOBULIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AREA UNDER THE CURVE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; BIOMICS; BREAST CANCER; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9; CLASSIFICATION; DATA ANALYSIS; DATA MINING; DECISION TREE; DIAGNOSTIC VALUE; GENE EXPRESSION; GENE SET ENRICHMENT ANALYSIS; GENERALLY APPLICABLE GENE SET ENRICHMENT; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; K NEAREST NEIGHBOR; OVARY CANCER; PARAMETRIC ANALYSIS OF GENE SET ENRICHMENT; PATIENT MONITORING; PRINCIPAL COMPONENT ANALYSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN PROTEIN INTERACTION; RANDOM FOREST; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SUPPORT VECTOR MACHINE; TREND STUDY;

EID: 84871556673     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.718329     Document Type: Review

References (96)

1. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5(11):845-56
2. Executive summary: standards of medical care in diabetes. Diabetes Care 2010;33(Suppl 1):S4-S10
3. Kim C, Tang G, Pogue-Geile KL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol 2011;29(31):4160-7
4. Konecny G, Slamon DJ. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park) 2002;16(11):1576; 1578
5. Friedman LS, Ostermeyer EA, Lynch ED, et al. The search for BRCA1. Cancer Res 1994;54(24):6374-82
6. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10(7):705-13
7. Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000;16(2):69-74
8. Bast RC Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010;116(12):2850-3
9. Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010;19(12):2995-9
10. Zhang Z, Yu Y, Xu F, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007;107(3):526-31
11. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64(16):5882-90
12. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(11):762-71
13. Daberkow D II. Screening for asymptomatic cancers. J La State Med Soc 1997;149(8):285-90
14. Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17(10):2872-81
15. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005;102(21):7677-82
16. Merritt MA, Parsons PG, Newton TR, et al. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer 2009;9:378
17. Amonkar SD, Bertenshaw GP, Chen TH, et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 2009;4(2):e4599
18. Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28(13):2159-66
19. Mok SC, Wong KK, Chan RK, et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994;52(2):247-52
20. Palmer C, Duan X, Hawley S, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 2008;3(7):e2633
21. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347(25):1999-2009
22. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26
23. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355(6):560-9
24. Mosley JD, Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics 2008;1:11
25. Desmedt C, Sotiriou C. Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle 2006;5(19):2198-202
26. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 2011;7(10):e1002240
27. Guttery DS, Hancox RA, Mulligan KT, et al. Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res 2010;12(4):R57
28. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011;343:d4411
29. Nugent R, Meila M. An overview of clustering applied to molecular biology. Methods Mol Biol 2010;620:369-404
30. Boutros PC, Okey AB. Unsupervised pattern recognition: an introduction to the whys and wherefores of clustering microarray data. Brief Bioinform 2005;6(4):331-43
31. O'Dwyer D, Ralton LD, O'Shea A, Murray GI. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS ONE 2011;6(11):e27718
32. Conrads TP, Anderson GA, Veenstra TD, et al. Utility of accurate mass tags for proteome-wide protein identification. Anal Chem 2000;72(14):3349-54
33. Anil J. Data clustering: 50 years beyond K-means. Pattern Recognit Lett 2010;31(8):651-66
34. Kerr G, Ruskin HJ, Crane M, Doolan P. Techniques for clustering gene expression data. Comput Biol Med 2008;38(3):283-93
35. Madeira SC, Oliveira AL. Biclustering algorithms for biological data analysis: a survey. IEEE/ACM Trans Comput Biol Bioinform 2004;1(1):24-45
36. Aranday-Cortes E, Hogarth PJ, Kaveh DA, et al. Transcriptional profiling of disease-induced host responses in bovine tuberculosis and the identification of potential diagnostic biomarkers. PLoS ONE 2012;7(2):e30626
37. Zhang J, Xiang Y, Ding L, et al. Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia. BMC Bioinformatics 2010;11(Suppl 9):S5
38. Zucknick M, Richardson S, Stronach EA. Comparing the characteristics of gene expression profiles derived by univariate and multivariate classification methods. Stat Appl Genet Mol Biol 2008;7(1; Article7
39. Wang H, Gottfries J, Barrenas F, Benson M. Identification of novel biomarkers in seasonal allergic rhinitis by combining proteomic, multivariate and pathway analysis. PLoS One 2011;6(8):e23563
40. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Jama 2010;304(24):2706-15
41. Noble WS. What is a support vector machine? Nat Biotechnol 2006;24(12):1565-7
42. Barla A, Jurman G, Riccadonna S, et al. Machine learning methods for predictive proteomics. Brief Bioinform 2008;9(2):119-28
43. Schrauder MG, Strick R, Schulz-Wendtland R, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 2012;7(1):e29770
44. Johansson H, Lindstedt M, Albrekt AS, Borrebaeck CA. A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics 2011;12:399
45. Kingsford C, Salzberg SL. What are decision trees? Nat Biotechnol 2008;26(9):1011-13
46. Diaz-Uriarte R, Alvarez de Andres S. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006;7:3
47. O'Bryant SE, Xiao G, Barber R, et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One 2011;6(12):e28092
48. van Dijk SJ, Feskens EJ, Heidema AG, et al. Plasma protein profiling reveals protein clusters related to BMI and insulin levels in middle-aged overweight subjects. PLoS One 2010;5(12):e14422
49. Eddy JA, Sung J, Geman D, Price ND. Relative expression analysis for molecular cancer diagnosis and prognosis. Technol Cancer Res Treat 2010;9(2):149-59
50. Geman D, d'Avignon C, Naiman DQ, Winslow RL. Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol 2004;3; Article19
51. Raychaudhuri S, Stuart JM, Altman RB. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput 2000;455-66
52. Celton M, Malpertuy A, Lelandais G, de Brevern AG. Comparative analysis of missing value imputation methods to improve clustering and interpretation of microarray experiments. BMC Genomics 2010;11:15
53. Liew AW, Law NF, Yan H. Missing value imputation for gene expression data: computational techniques to recover missing data from available information. Brief Bioinform 2011;12(5):498-513
54. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8(1):3-15
55. Webb-Robertson BJM, Jarman KH, Harvey SD, et al. An improved optimization algorithm and Bayes factor termination criterion for sequential projection pursuit. Chemom Intell Lab Syst 2005;77(1-2):149-60
56. Webb-Robertson BJ, Jarman KH, Scott HD, et al. An improved optimization algorithm and a Bayes factor termination criterion for sequential projection pursuit. Chem Intell Lab Sys 2005;77:149-60
57. Webb-Robertson BJ, Matzke MM, Jacobs JM, et al. A statistical selection strategy for normalization procedures in LC-MS proteomics experiments through dataset-dependent ranking of normalization scaling factors. Proteomics 2011;11(24):4736-41
58. McDermott JE, Archuleta M, Thrall BD, et al. Controlling the response: predictive modeling of a highly central, pathogen-targeted core response module in macrophage activation. PLoS One 2011;6(2):e14673
59. Mason O, Verwoerd M. Graph theory and networks in Biology. IET Syst Biol 2007;1(2):89-119
60. McDermott JE, Archuleta M, Stevens SL, et al. Defining the players in higher-order networks: predictive modeling for reverse engineering functional influence networks. Pac Symp Biocomput 2011;314-25
61. Diamond DL, Syder AJ, Jacobs JM, et al. Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog 2010;6(1):e1000719
62. Yousef M, Ketany M, Manevitz L, et al. Classification and biomarker identification using gene network modules and support vector machines. BMC Bioinformatics 2009;10:337
63. Gavin AC, Aloy P, Grandi P, et al. Proteome survey reveals modularity of the yeast cell machinery. Nature 2006;440(7084):631-6
64. Aloy P, Pichaud M, Russell RB. Protein complexes: structure prediction challenges for the 21st century. Curr Opin Struct Biol 2005;15(1):15-22
65. Shoemaker BA, Panchenko AR. Deciphering protein-protein interactions. Part I. Experimental techniques and databases. PLoS Comput Biol 2007;3(3):e42
66. Xiong J, Liu J, Rayner S, et al. Protein-protein interaction reveals synergistic discrimination of cancer phenotype. Cancer Inform 2010;9:61-6
67. Dutkowski J, Ideker T. Protein networks as logic functions in development and cancer. PLoS Comput Biol 2011;7(9):e1002180
68. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009;461(7261):218-23
69. Emmert-Streib F, Glazko GV. Pathway analysis of expression data: deciphering functional building blocks of complex diseases. PLoS Comput Biol 2011;7(5):e1002053
70. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4(1):44-57
71. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102(43):15545-50
72. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34(3):267-73
73. Goeman JJ, Buhlmann P. Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics 2007;23(8):980-7
74. McDermott J, Shankaran H, Eisfeld A, et al. Conserved host response to highly pathogenic avian influenza virus infection in human cell culture, mouse and macaque model systems. BMC Syst Biol 2011; In press
75. Zhang F, Chen JY. Discovery of pathway biomarkers from coupled proteomics and systems biology methods. BMC Genomics 2010;11(Suppl 2):S12
76. Kim SY, Volsky DJ. PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics 2005;6:144
77. Jiang Z, Gentleman R. Extensions to gene set enrichment. Bioinformatics 2007;23(3):306-13
78. Luo W, Friedman MS, Shedden K, et al. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 2009;10:161
79. Irizarry RA, Wang C, Zhou Y, Speed TP. Gene set enrichment analysis made simple. Stat Methods Med Res 2009;18(6):565-75
80. Donnem T, Fenton CG, Lonvik K, et al. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One 2012;7(1):e29671
81. Schwarz JK, Payton JE, Rashmi R, et al. Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer. Clin Cancer Res 2012;18(5):1464-71
82. Evans JA, Rzhetsky A. Advancing science through mining libraries, ontologies, and communities. J Biol Chem 2011;286(27):23659-66
83. Tanabe L, Scherf U, Smith LH, et al. MedMiner: an Internet text-mining tool for biomedical information, with application to gene expression profiling. Biotechniques 1999;27(6):1210-1214; 1216-1217
84. Cohen KB, Hunter L. Getting started in text mining. PLoS Comput Biol 2008;4(1):e20
85. Krauthammer M, Nenadic G. Term identification in the biomedical literature. J Biomed Inform 2004;37(6):512-26
86. Rzhetsky A, Seringhaus M, Gerstein MB. Getting started in text mining: part two. PLoS Comput Biol 2009;5(7):e1000411
87. Rodriguez-Esteban R. Biomedical text mining and its applications. PLoS Comput Biol 2009;5(12):e1000597
88. Jenssen TK, Laegreid A, Komorowski J, Hovig E. A literature network of human genes for high-throughput analysis of gene expression. Nat Genet 2001;28(1):21-8
89. Deng X, Geng H, Bastola DR, Ali HH. Link test-a statistical method for finding prostate cancer biomarkers. Comput Biol Chem 2006;30(6):425-33
90. Ongenaert M, Van Neste L, De Meyer T, et al. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 2008;36(Database issue):D842-6
91. Ongenaert M. Epigenetic databases and computational methodologies in the analysis of epigenetic datasets. Adv Genet 2010;71:259-95
92. Feng Z, Prentice R, Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004;5(6):709-19
93. Jiang W, Simon R. A comparison of bootstrap methods and an adjusted bootstrap approach for estimating the prediction error in microarray classification. Stat Med 2007;26(29):5320-34
94. Mukherjee S, Pelech S, Neve RM, et al. Sparse combinatorial inference with an application in cancer biology. Bioinformatics 2009;25(2):265-71
95. Hill SM, Neve RM, Bayani N, et al. Integrating biological knowledge into variable selection: an empirical Bayes approach with an application in cancer biology. BMC Bioinformatics 2012;13(1):94
96. Atkinson AJ Jr, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95